Clinical Trials
7 trialsNCT05070403 2026-04-01
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT04533321 2020-08-31
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
National University Hospital, Singapore
Phase 2 Unknown
NCT03652233 2019-06-20
Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT02271906 2019-04-30
The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03486509 2018-04-03
Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Unknown
NCT01345682 2018-02-15
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed
NCT00514943 2016-07-26
BIBW 2992 (Afatinib) in Head & Neck Cancer
Boehringer Ingelheim
Phase 2 Completed